An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis
Public ClinicalTrials.gov record NCT00751881. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study was to assess the effect of two doses of teriflunomide, in comparison to placebo, on the frequency of multiple sclerosis (MS) relapses in participants with relapsing MS. Key secondary objective was to assess the effect of the two doses of teriflunomide, in comparison to placebo, on disability progression. Other secondary objectives were: * To assess the effect of the two doses of teriflunomide in comparison to placebo on: * Fatigue; * Health-related quality of life, a measure of the impact of the participant's health on his or her overall well being. * To evaluate the safety and tolerability of teriflunomide.
Study identification
- NCT ID
- NCT00751881
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,169 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2008
- Primary completion
- Mar 31, 2012
- Completion
- Jul 31, 2015
- Last update posted
- Jul 6, 2016
2008 – 2015
United States locations
- U.S. sites
- 39
- U.S. states
- 25
- U.S. cities
- 38
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sanofi-Aventis Investigational Site Number 840041 | Phoenix | Arizona | 85060 | — |
| Sanofi-Aventis Investigational Site Number 840084 | Tucson | Arizona | 85741-3537 | — |
| Sanofi-Aventis Investigational Site Number 840008 | Loma Linda | California | 92354 | — |
| Sanofi-Aventis Investigational Site Number 840034 | Modesto | California | 95355 | — |
| Sanofi-Aventis Investigational Site Number 840090 | Fort Collins | Colorado | 80528 | — |
| Sanofi-Aventis Investigational Site Number 840011 | Fairfield | Connecticut | 06430 | — |
| Sanofi-Aventis Investigational Site Number 840013 | Maitland | Florida | 32761 | — |
| Sanofi-Aventis Investigational Site Number 840083 | Ocala | Florida | 34474 | — |
| Sanofi-Aventis Investigational Site Number 840086 | Ormond Beach | Florida | 32174 | — |
| Sanofi-Aventis Investigational Site Number 840025 | Sarasota | Florida | 34239 | — |
| Sanofi-Aventis Investigational Site Number 840015 | St. Petersburg | Florida | 33606 | — |
| Sanofi-Aventis Investigational Site Number 840033 | Sunrise | Florida | 33351 | — |
| Sanofi-Aventis Investigational Site Number 840063 | Elk Grove Village | Illinois | 60007 | — |
| Sanofi-Aventis Investigational Site Number 840064 | Flossmoor | Illinois | 60402 | — |
| Sanofi-Aventis Investigational Site Number 840039 | Fort Wayne | Indiana | 46804 | — |
| Sanofi-Aventis Investigational Site Number 840012 | Indianapolis | Indiana | 46256 | — |
| Sanofi-Aventis Investigational Site Number 840016 | Des Moines | Iowa | 50314 | — |
| Sanofi-Aventis Investigational Site Number 840069 | Clinton Township | Michigan | 48035 | — |
| Sanofi-Aventis Investigational Site Number 840075 | Grand Rapids | Michigan | 49503 | — |
| Sanofi-Aventis Investigational Site Number 840061 | Traverse City | Michigan | 49684 | — |
| Sanofi-Aventis Investigational Site Number 840076 | Minneapolis | Minnesota | 55455 | — |
| Sanofi-Aventis Investigational Site Number 840079 | Tupelo | Mississippi | 38801 | — |
| Sanofi-Aventis Investigational Site Number 840088 | St Louis | Missouri | 63131 | — |
| Sanofi-Aventis Investigational Site Number 840060 | Syracuse | New York | 13210 | — |
| Sanofi-Aventis Investigational Site Number 840029 | Charlotte | North Carolina | 28204 | — |
| Sanofi-Aventis Investigational Site Number 840074 | Bismarck | North Dakota | 58501 | — |
| Sanofi-Aventis Investigational Site Number 840026 | Cincinnati | Ohio | 45219 | — |
| Sanofi-Aventis Investigational Site Number 840078 | Dayton | Ohio | 45409 | — |
| Sanofi-Aventis Investigational Site Number 840066 | Tulsa | Oklahoma | 74137 | — |
| Sanofi-Aventis Investigational Site Number 840024 | Portland | Oregon | 97225 | — |
| Sanofi-Aventis Investigational Site Number 840073 | Philadelphia | Pennsylvania | 19102 | — |
| Sanofi-Aventis Investigational Site Number 840022 | Philadelphia | Pennsylvania | 19107 | — |
| Sanofi-Aventis Investigational Site Number 840068 | Greenville | South Carolina | 29615 | — |
| Sanofi-Aventis Investigational Site Number 840071 | Cordova | Tennessee | 38018 | — |
| Sanofi-Aventis Investigational Site Number 840036 | Nashville | Tennessee | 37232 | — |
| Sanofi-Aventis Investigational Site Number 840007 | San Antonio | Texas | 78229 | — |
| Sanofi-Aventis Investigational Site Number 840006 | Bennington | Vermont | 05201 | — |
| Sanofi-Aventis Investigational Site Number 840089 | Seattle | Washington | 98122 | — |
| Sanofi-Aventis Investigational Site Number 840020 | Charleston | West Virginia | 25301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 154 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00751881, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 6, 2016 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00751881 live on ClinicalTrials.gov.